Sporadic Creutzfeldt-Jakob disease represents the most common form of human prion disease, characterized by rapid neurodegeneration and heterogeneous clinical presentations. Historically, clinicians and researchers have attributed this broad variability to differences in age at symptom onset, host PRNP codon 129 polymorphisms, and specific conformational prion strains. However, the exact role of biological sex in modulating disease presentation and clinical trajectories has remained largely unresolved. A large registry-based cohort study now provides compelling evidence that biological sex significantly influences early neuropsychiatric symptoms, functional decline timelines, and overall survival duration in affected individuals.

Heterogeneity in Sporadic Creutzfeldt-Jakob Disease Phenotypes

Prion disorders develop when normal cellular prion protein undergoes a conformational shift into pathological, self-propagating misfolded isoforms. In patients with sporadic Creutzfeldt-Jakob disease, this molecular cascade drives widespread neuronal loss, spongiform change, and profound astrogliosis throughout the central nervous system. Consequently, patients present with rapidly progressive cognitive impairment, cerebellar ataxia, myoclonus, and various visual disturbances. Diagnostic confirmation in life has improved dramatically following the widespread adoption of real-time quaking-induced conversion (RT-QuIC) assays in cerebrospinal fluid, which provide extraordinary specificity for pathological prion seeding activity.

Despite these technological advances, predicting the exact trajectory of functional loss for individual patients remains difficult. Investigators analyzed a well-characterized cohort of 599 definite or probable RT-QuIC-supported cases, comprising 313 women and 286 men. Interestingly, the biological age at disease onset did not differ significantly between male and female cohorts. Nevertheless, detailed multivariate analyses revealed marked sex-specific disparities across downstream clinical milestones. Recognizing these divergent phenotypic trajectories allows clinicians to refine prognostic discussions, anticipate supportive care needs, and better understand the underlying biology of human prion pathology.

Distinct Clinical Manifestations Between Men and Women

The clinical spectrum of prion disease often begins with subtle, non-specific neurological or psychiatric complaints that can misdirect initial diagnostic investigations. In the cohort analysis, false discovery rate (FDR)-corrected univariate evaluations revealed notable differences in early symptom patterns between sexes. Specifically, female patients exhibited a significantly higher frequency of mood disorders at initial disease onset compared to male counterparts. As the neurodegenerative process advanced toward formal case notification, women continued to demonstrate higher rates of anxiety disorders, depressive mood symptoms, falls, and focal dystonia.

To evaluate whether these patterns reflected broader systemic differences, researchers implemented hierarchical logistic regression models adjusted for established disease modifiers, including age at onset and PRNP codon 129 genotypes. These adjusted models strongly supported an overall sex-related divergence in the clinical profile. Although individual clinical feature coefficients did not retain isolated significance after stringent FDR correction, the aggregate clinical landscape clearly diverged between sexes. Consequently, medical teams evaluating older female patients presenting with unexplained, rapidly emerging affective syndromes alongside movement abnormalities must maintain heightened clinical vigilance for underlying prion neurodegeneration.

Functional Decline and Time to Bedridden State

Loss of mobility represents a pivotal milestone in the natural history of rapidly progressive neurodegenerative conditions. It heralds severe debility, escalates nursing care requirements, and increases vulnerability to secondary systemic complications such as aspiration pneumonia and decubitus ulcers. In this study, the time elapsed from initial symptom onset to reaching a bedridden state differed dramatically according to patient sex. Female patients maintained ambulatory function significantly longer than male patients, experiencing a median latency of five months before becoming bedridden, compared to just three months among males.

Furthermore, Cox proportional hazards regression models adjusted for age at onset and PRNP codon 129 status established that male sex is an independent predictor of accelerated motor deterioration. Specifically, male patients demonstrated a 31% higher hazard of rapid progression to a bedridden state (HR = 1.31; p = 0.042). Importantly, this elevated risk persisted and even strengthened after incorporating comorbid medical conditions into the statistical models (HR = 1.56; p = 0.021). Therefore, clinicians managing male patients should anticipate a substantially steeper trajectory of functional decline and initiate mobility preservation strategies and caregiver support systems earlier in the disease course.

Survival Disparities and Hazard Ratios Across Sexes

In addition to slower motor decline, female patients demonstrated significantly longer overall disease duration from symptom onset to death. Survival analyses confirmed that biological sex serves as an independent prognostic indicator in human prion pathology. Male patients experienced a significantly higher hazard of mortality relative to females (HR = 1.25; p = 0.012), even after comprehensive adjustment for established prognostic determinants such as host genetics and onset age. This disparity underscores that sex-specific biological pathways actively modulate the tempo of fatal neurodegeneration.

The biological mechanisms underlying these differences warrant extensive future investigation. Neuroprotective effects mediated by endogenous estrogens, variations in neuroinflammatory microglial activation, and differential baseline expression of cellular prion proteins may contribute to the slower disease progression observed in females. Alternatively, sex-specific differences in innate immune responses or metabolic resilience against proteotoxic stress might mitigate the velocity of neuronal destruction. Regardless of the precise molecular mechanisms, incorporating biological sex into clinical stratification improves the precision of survival estimates and provides valuable context when designing future therapeutic trials.

Diagnostic and Palliative Care Considerations for Clinicians

The identification of sex-dependent disease trajectories carries immediate practical value for neurology teams, geriatricians, and palliative care specialists. Because female patients frequently present with prominent psychiatric features, such as anxiety and depression, clinicians must avoid prematurely attributing rapid functional deterioration solely to primary psychiatric illnesses. Comprehensive diagnostic workups—including brain magnetic resonance imaging with diffusion-weighted sequences, electroencephalography, and cerebrospinal fluid RT-QuIC testing—remain essential whenever unexplained cognitive decline accompanies affective changes.

Moreover, understanding these disparate disease timelines improves palliative and end-of-life planning. Because male patients face accelerated trajectories toward akinetic mutism and total bed confinement, care teams must establish advance directives and palliative care consultations promptly upon diagnosis. Conversely, because female patients experience a more prolonged course with elevated frequencies of dystonia and affective distress, targeted symptomatic pharmacotherapy and fall-prevention measures become central to maintaining quality of life. Multidisciplinary coordination between neurologists, psychiatrists, physical therapists, and palliative teams ensures individualized, compassionate care across all phases of the disease.

Future Directions in Prion Disease Research and Biomarker Development

These registry findings highlight the necessity of integrating biological sex as a key variable in preclinical and clinical prion research. Previous observational cohorts have often grouped patient populations without disaggregating endpoints by sex, potentially masking meaningful subgroup effects. Future investigations should examine whether fluid biomarkers of neuronal injury, such as total tau, neurofilament light chain (NfL), and 14-3-3 protein, exhibit sex-specific kinetic profiles during disease evolution. Furthermore, preclinical therapeutic trials evaluating anti-prion compounds, antisense oligonucleotides, or monoclonal antibodies must stratify efficacy analyses by sex to capture differential pharmacodynamic responses accurately.

Frequently Asked Questions (FAQs)

How does patient sex influence clinical presentations in sporadic Creutzfeldt-Jakob disease?

Biological sex significantly affects early clinical manifestations in human prion disease. Female patients demonstrate a notably higher incidence of mood disorders at disease onset, as well as increased frequencies of anxiety, affective disturbance, dystonia, and falls during clinical notification, whereas overall age at onset remains comparable between sexes.

Why do female patients with sporadic Creutzfeldt-Jakob disease survive longer?

Female patients exhibit a slower rate of functional decline and extended survival. Potential biological mechanisms include neuroprotective hormonal effects, differences in microglial-mediated neuroinflammation, and divergent cellular resilience against toxic prion aggregates. Consequently, male patients demonstrate an independent 25% higher hazard of mortality and faster functional deterioration.

What role does RT-QuIC testing play in confirming sporadic Creutzfeldt-Jakob disease?

The real-time quaking-induced conversion (RT-QuIC) assay detects minute quantities of misfolded, disease-associated prion protein in cerebrospinal fluid. It delivers exceptionally high diagnostic sensitivity and specificity, allowing clinicians to achieve accurate in-life diagnostic confirmation, eliminate invasive brain biopsies, and distinguish prion disorders from treatable rapid neurodegenerative conditions.

Disclaimer: This content is for informational and educational purposes only and is not intended to serve as medical advice, diagnosis, or treatment. It does not replace professional clinical judgment. Healthcare providers should always independently verify information, consult primary medical literature, and evaluate individual patient circumstances before making clinical decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Costanzo M et al. Sex differences in disease trajectories of sporadic creutzfeldt-jakob disease: a registry-based cohort study. J Neurol. 2026 Aug 26. doi: 10.1007/s00415-026-14074-8. PMID: 42645534.


2. Hermann P, Appleby B, Brandel JP, et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol. 2021;20(3):235-246.


3. Watson N, Brandel JP, Green A, et al. The revised European Creutzfeldt-Jakob Disease Surveillance Network diagnostic criteria for sporadic Creutzfeldt-Jakob disease: an evaluation with updated data. Neurobiol Aging. 2022;114:106-112.